Market Overview:
The global rheumatic heart disease market is expected to grow at a CAGR of 5.5% from 2018 to 2030. The growth in the market can be attributed to factors such as rising incidence of rheumatic heart disease, increasing awareness about the condition, and technological advancements in diagnosis and treatment of the condition. However, lack of awareness about rheumatic heart disease in developing countries is expected to restrain the growth of this market during the forecast period. On the basis of type, the global rheumatic heart disease market is segmented into myocarditis and pericarditis. Myocarditis accounted for a larger share than pericarditis in 2017 and is expected to maintain its lead during the forecast period. On the basis of application, hospitals accounted for a larger share than diagnostic centres and research centres in 2017; however, diagnostic centres are projected to register higher CAGR during 2018-2030 owing to increasing demand for early diagnosis and treatment options for patients with suspected or confirmed cases of rheumatic heart disease.
Product Definition:
Rheumatic heart disease is a type of cardiomyopathy caused by rheumatic fever. It is the most common acquired heart disease in childhood, and can lead to congestive heart failure, stroke, and death.
Myocarditis:
Myocarditis is a heart muscle inflammation. It can be classified as acute or chronic based on the duration for which symptoms last. Acute myocarditis usually lasts for less than 6 months and is characterized by high fever, severe heart pain, and sweating; whereas, chronic myocarditis extends over a period of 6 months to 5 years and leads to left ventricular failure.
Pericarditis:
Pericarditis is a inflammation of the pericardium, which is the sac that encloses the heart. The most common symptom of pericarditis is chest pain. Pericardial effusion refers to a collection of fluid around the heart and has several causes such as infection, trauma, and surgery.
Application Insights:
Based on the application, the global market is segmented into hospital, diagnostic center and research center. The hospital segment dominated the market in 2017 owing to a large patient base with rheumatic heart diseases. According to estimates published by WHO in 2018, around 1% of population of Europe suffers from rheumatic heart disease every year. In addition, according to European Society for Cardiology (ESC), around 2 million people are affected by RHD across Europe annually which requires about 300 thousand surgeries and kills more than 20 thousand patients each year.
Regional Analysis:
North America dominated the global market in terms of revenue share in 2017. The presence of a large number of rheumatic disease patients, favorable reimbursement scenario, and high healthcare expenditure are some factors attributing to its largest share. In addition, increasing prevalence of infectious diseases is also expected to boost the demand for RHD medicines over the forecast period.
Asia Pacific is anticipated to witness lucrative growth during the forecast period owing to improving economic conditions and rising disposable income levels in emerging countries such as China & India. Furthermore, an increase in foreign investments coupled with government support has led to an improvement in healthcare infrastructure which will further drive growth over next eight years.
Growth Factors:
- Increasing incidence of rheumatic heart disease due to changing lifestyles and increasing population
- Growing awareness about the symptoms and treatment options for rheumatic heart disease
- Rising number of people with risk factors for developing rheumatic heart disease, such as exposure to strep throat infections
- Availability of new and innovative treatments for rheumatic heart disease
- Growing demand for better diagnosis and treatment options for patients with rheumatic heart disease
Scope Of The Report
Report Attributes
Report Details
Report Title
Rheumatic Heart Disease Market Research Report
By Type
Myocarditis, Pericarditis
By Application
Hospital, Diagnostic Centre, Research Centre
By Companies
Abbott Laboratories, Bayer, BIOTRONIK, Boston Scientific, Bristol-Myers Squibb, C. R. Bard, Cardinal Health, Cook Medical, Roche, GE Healthcare, InterValve, Novartis, On-X Life Technologies, Osypka Medical, Otsuka, PerkinElmer, Pfizer, Reckitt Benckiser, Siemens Healthineers, Toray
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
172
Number of Tables & Figures
121
Customization Available
Yes, the report can be customized as per your need.
Global Rheumatic Heart Disease Market Report Segments:
The global Rheumatic Heart Disease market is segmented on the basis of:
Types
Myocarditis, Pericarditis
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Hospital, Diagnostic Centre, Research Centre
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Abbott Laboratories
- Bayer
- BIOTRONIK
- Boston Scientific
- Bristol-Myers Squibb
- C. R. Bard
- Cardinal Health
- Cook Medical
- Roche
- GE Healthcare
- InterValve
- Novartis
- On-X Life Technologies
- Osypka Medical
- Otsuka
- PerkinElmer
- Pfizer
- Reckitt Benckiser
- Siemens Healthineers
- Toray
Highlights of The Rheumatic Heart Disease Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Myocarditis
- Pericarditis
- By Application:
- Hospital
- Diagnostic Centre
- Research Centre
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Rheumatic Heart Disease Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Rheumatic heart disease is a condition in which the heart muscle becomes inflamed and damaged. This can cause difficulty in pumping blood throughout the body, and may lead to chest pain, shortness of breath, or even death. Rheumatic heart disease is most commonly caused by an autoimmune disorder (a condition in which the immune system attacks healthy tissue), but can also be caused by other factors, such as infection or injury.
Some of the key players operating in the rheumatic heart disease market are Abbott Laboratories, Bayer, BIOTRONIK, Boston Scientific, Bristol-Myers Squibb, C. R. Bard, Cardinal Health, Cook Medical, Roche, GE Healthcare, InterValve, Novartis, On-X Life Technologies, Osypka Medical, Otsuka, PerkinElmer, Pfizer, Reckitt Benckiser, Siemens Healthineers, Toray.
The rheumatic heart disease market is expected to grow at a compound annual growth rate of 5.5%.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Rheumatic Heart Disease Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Rheumatic Heart Disease Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Rheumatic Heart Disease Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Rheumatic Heart Disease Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Rheumatic Heart Disease Market Size & Forecast, 2020-2028
4.5.1 Rheumatic Heart Disease Market Size and Y-o-Y Growth
4.5.2 Rheumatic Heart Disease Market Absolute $ Opportunity
Chapter 5 Global Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Market Size Forecast by Type
5.2.1 Myocarditis
5.2.2 Pericarditis
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Market Size Forecast by Applications
6.2.1 Hospital
6.2.2 Diagnostic Centre
6.2.3 Research Centre
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Rheumatic Heart Disease Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Rheumatic Heart Disease Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Analysis and Forecast
9.1 Introduction
9.2 North America Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Market Size Forecast by Type
9.6.1 Myocarditis
9.6.2 Pericarditis
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Market Size Forecast by Applications
9.10.1 Hospital
9.10.2 Diagnostic Centre
9.10.3 Research Centre
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Analysis and Forecast
10.1 Introduction
10.2 Europe Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Market Size Forecast by Type
10.6.1 Myocarditis
10.6.2 Pericarditis
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Market Size Forecast by Applications
10.10.1 Hospital
10.10.2 Diagnostic Centre
10.10.3 Research Centre
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Market Size Forecast by Type
11.6.1 Myocarditis
11.6.2 Pericarditis
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Market Size Forecast by Applications
11.10.1 Hospital
11.10.2 Diagnostic Centre
11.10.3 Research Centre
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Analysis and Forecast
12.1 Introduction
12.2 Latin America Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Market Size Forecast by Type
12.6.1 Myocarditis
12.6.2 Pericarditis
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Market Size Forecast by Applications
12.10.1 Hospital
12.10.2 Diagnostic Centre
12.10.3 Research Centre
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Market Size Forecast by Type
13.6.1 Myocarditis
13.6.2 Pericarditis
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Market Size Forecast by Applications
13.10.1 Hospital
13.10.2 Diagnostic Centre
13.10.3 Research Centre
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Rheumatic Heart Disease Market: Competitive Dashboard
14.2 Global Rheumatic Heart Disease Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Abbott Laboratories
14.3.2 Bayer
14.3.3 BIOTRONIK
14.3.4 Boston Scientific
14.3.5 Bristol-Myers Squibb
14.3.6 C. R. Bard
14.3.7 Cardinal Health
14.3.8 Cook Medical
14.3.9 Roche
14.3.10 GE Healthcare
14.3.11 InterValve
14.3.12 Novartis
14.3.13 On-X Life Technologies
14.3.14 Osypka Medical
14.3.15 Otsuka
14.3.16 PerkinElmer
14.3.17 Pfizer
14.3.18 Reckitt Benckiser
14.3.19 Siemens Healthineers
14.3.20 Toray
